Myriad Genetics (MYGN) Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris

Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction (ARR) into the Prolaris^® Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy. Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT)¹.

ADT can be effective at slowing the progression of prostate cancer, but it can also be associated with significant side effects such as bone and muscle loss, weight gain and increased cardiovascular risk. In addition to helping identify those patients who can safely forego ADT, the latest Prolaris enhancement will now provide patients with an individual assessment of how adding ADT to radiation therapy may reduce their risk of metastasis over 10 years.

“When men are diagnosed with localized prostate cancer, they have choices about different kinds of therapies. Often they’re considering combining therapies together or just doing an individual therapy,” said Dr. Jonathan Tward, MD, PhD, at the Huntsman Cancer Institute at the University of Utah. “With the Prolaris test physicians can now counsel patients on whether adding ADT to their treatment plan may reduce their individualized risk of metastasis. This offers increased clarity to make informed decisions, balancing the potential side effects of ADT.”

At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Tward presented a study that found Prolaris can predict the ARR of metastasis when ADT is added to RT regardless of National Comprehensive Cancer Network^® risk group. When a patient’s Prolaris results fell below the multi-modal treatment threshold, adding ADT to RT resulted in an average ARR of 0.86%, implying minimal benefits against potential side effects. However, for those above the threshold, adding ADT to RT yielded an average ARR of 8.2%, indicating a more meaningful benefit from ADT that could outweigh the possible side effects.

“Determining how much a patient benefits from ADT versus the side effects is critical to making the best treatment decisions for patients with prostate cancer,” said Terry White, General Manager of Urology, Myriad Genetics. “With the addition of Absolute Risk Reduction to the Prolaris report, patients and their providers can have a more personalized risk-benefit discussion and decide on the most effective treatment path.”

You May Also Be Interested In

• Cingulate (CING) Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103
• Presto (PRST) Names Kat Hoffman-Flynt Chief Operating Officer
• Akari Therapeutcis (AKTX) Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors